IVUS-Guided Sirolimus-Coated Balloon Versus Sirolimus-Eluting Stent for De Novo Large Vessel Lesions in ACS

Study acronym: IVUS-SCB
StatusNot Yet Recruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2027 → Dec 31, 2028
See other at-risk trials from China National Center for Cardiovascular Diseases

Record History

  1. Notable Primary completion pushed from Dec 31, 2027 to Dec 31, 2028
    • Start date pushed from Sep 1, 2026 to Dec 1, 2026
    • Study completion pushed from May 1, 2028 to Jan 30, 2029
  2. Minor Secondary endpoints: details revised at 1 of 18 entries
  3. Minor Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this interventional study is to evaluate the efficacy and safety of an intravascular ultrasound (IVUS)-guided sirolimus-coated balloon (SCB)-based strategy versus planned sirolimus-eluting stent (SES) implantation in patients with acute coronary syndrome (ACS) and de novo large-vessel coronary lesions. The main question is whether the SCB-based strategy is non-inferior to the SES strategy with respect to in-segment late lumen loss (LLL) at 9 months. Following adequate lesion preparation and confirmation according to the prespecified angiographic and IVUS criteria that the target lesion is suitable for both randomized treatment strategies, participants will be randomly assigned to undergo either SCB treatment without routine stent implantation or planned SES implantation. In the SCB group, bail-out SES implantation will be performed when clinically necessary, such as in cases of significant residual stenosis or flow-limiting dissection. Participants will undergo angiographic and IVUS follow-up at 9 months, and clinical outcomes will be assessed through 12 months.
Trial Details
NCT Number NCT07796412
Lead Sponsor China National Center for Cardiovascular Diseases
Collaborators: B. Braun Medical International Trading Company Ltd.
Conditions
(from sponsor)
Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Related terms Acute Coronary Syndrome
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov